Shattuck Labs reports Q2 net loss of $23.6M; pipeline advances with SL-172154 and SL-279252

Shattuck Labs, Inc.

2021-Q2 EPS reported -$0.85 revenue$-1,961,000

Net loss $23.6M ($0.56 loss per share) vs $6.2M ($0.81 loss per share) in Q2 2020; revenue negative $4.2M due to Takeda collaboration cost changes.
Cash and investments $304.8M as of June 30, 2021; cash runway expected through 2024, beyond Phase 1 results.
SL-172154 Phase 1 in ovarian cancer: dose escalation at 3.0 mg/kg, plans to advance to 10.0 mg/kg; no dose-limiting toxicities observed.
SL-279252 Phase 1: additional dose cohorts at 12.0 and 24.0 mg/kg based on pharmacodynamic data; SITC abstracts submitted for November 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.